Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

Activating mutations of FLT3 contribute to deregulated hematopoietic stem and progenitor cell (HSC/Ps) growth and survival in patients with acute myeloid leukemia (AML), leading to poor overall survival. AML patients treated with investigational drugs targeting mutant FLT3, including Quizartinib and...

Full description

Bibliographic Details

Published in:	The Journal of Clinical Investigation
Main Authors:	Baskar Ramdas, Neetu Dayal, Ruchi Pandey, Elizabeth Larocque, Rahul Kanumuri, Santhosh Kumar Pasupuleti, Sheng Liu, Chrysi Kanellopoulou, Elizabeth Fei Yin Chu, Rodrigo Mohallem, Saniya Virani, Gaurav Chopra, Uma K. Aryal, Rena Lapidus, Jun Wan, Ashkan Emadi, Laura S. Haneline, Frederick W. Holtsberg, M. Javad Aman, Herman O. Sintim, Reuben Kapur
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2024-06-01
Subjects:	Hematology Stem cells
Online Access:	https://doi.org/10.1172/JCI169245